There are currently 433 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT04768426
Recruiting
The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes in ctDNA in the blood over time received during capecitabine treatment. Results of ctDNA analysis will be correlated to genetic characteristics of individual tumors. This may inform future clinical tria... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Stanford University, Stanford, California
Conditions: Triple Negative Breast Cancer, Breast Cancer
Register for Updates
[18F] F-GLN by PET/CT in Breast Cancer
NCT03863457
Recruiting
Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC). This... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Register for Updates
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
NCT05989347
Recruiting
The primary objective of the study is to assess metabolic plasma markers of insulin resistance in patients with early-stage HER2-negative breast cancers receiving dapagliflozin concomitant with neoadjuvant therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Yale Cancer Center Smilow Cancer Hospital, New Haven, Connecticut
Conditions: Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer
Register for Updates
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
NCT06435351
Recruiting
This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
NCT06347068
Recruiting
This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Breast Cancer, Relapse, Resistant Cancer, Triple Negative Breast Cancer
Register for Updates
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain MetAstaSEs
NCT06176261
Recruiting
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Miami Baptist Cancer Institute/, Miami, Florida +2 locations
Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Register for Updates
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
NCT06833502
Recruiting
The purpose of the study is to determine the frequency of systemic metastasis in node positive breast cancer following chemotherapy and surgery. Participants will be asked to spend about 6 months in this study. Participants will undergo a computed tomography (CT) screening of the thorax, abdomen, and pelvis at baseline prior to adjuvant radiation therapy and another CT screening of the thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Node-positive Breast Cancer
Register for Updates
African Cancer Genome: GMD
NCT05754658
Recruiting
The goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of African ancestry. The study is conducted by the African Caribbean Cancer Consortium (AC3) and involves the recruitment of patients from nine international AC3 research sites in the Bahamas, Barbados, Benin, Burkina Faso, Haiti, Jamaica, Kenya, Namibia, and Trinidad and Tobago, and the US. The main questions are to: molecularly characterize genomic... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/11/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Breast Cancer, Prostate Cancer
Register for Updates
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
NCT05269160
Recruiting
Radiotherapy is a mainstay of treatment in breast cancer treatment, in the adjuvant setting. Radiation dermatitis occurs in up to 65% of these patients; currently, there is no standard of care for this treatment-related toxicity. The aim of this study is to investigate the safety and tolerability (Phase I) and preliminary efficacy (Phase II) of prophylactic esomeprazole cream (termed "Dermaprazole") in patients who require radiation for breast cancer in the adjuvant setting.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/10/2025
Locations: Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas +2 locations
Conditions: Radiation Dermatitis, Breast Cancer
Register for Updates
Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT04841148
Recruiting
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Georgetown University, Washington, DC, District of Columbia +6 locations
Conditions: Breast Cancer
Register for Updates
3D Printed Breast Models in the Surgical Management of Breast Cancer
NCT05755984
Recruiting
To learn if providing a 3-D printed model of the breast can help breast cancer patients make decisions related to their care. During this study, some study participants will receive the 3-D printed model and some study participants will receive traditional breast imaging scans to learn if the 3-D printed model
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer
NCT03742245
Recruiting
The purpose of this study is to test the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Houston Methodist Cancer Center, Houston, Texas
Conditions: Breast Cancer Metastatic, Breast Cancer
Register for Updates